Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-12154

Landmesser, U; Wollert, K C; Drexler, H (2009). Potential novel pharmacological therapies for myocardial remodelling. Cardiovascular Research, 81(3):519-527.

[img] PDF - Registered users only
1MB

View at publisher
[img]
Preview
Accepted Version
PDF
1MB

Abstract

Left ventricular (LV) remodelling remains an important treatment target in patients after myocardial infarction (MI) and chronic heart failure (CHF). Accumulating evidence has supported the concept that beneficial effects of current pharmacological treatment strategies to improve the prognosis in these patients, such as angiotensin-converting enzyme (ACE) inhibition, angiotensin type 1 receptor blocker therapy, and beta-blocker therapy, are related, at least in part, to their effects on LV remodelling and dysfunction. However, despite modern reperfusion therapy after MI and optimized treatment of patients with CHF, LV remodelling is observed in a substantial proportion of patients and is associated with an adverse clinical outcome. These observations call for novel therapeutic strategies to prevent or even reverse cardiac remodelling. Recent insights from experimental studies have provided new targets for interventions to prevent or reverse LV remodelling, i.e. reduced endothelial nitric oxide (NO) synthase-derived NO availability, activation of cardiac and leukocyte-dependent oxidant stress pathways, inflammatory pathway activation, matrix-metalloproteinase activation, or stem cell transfer and delivery of novel paracrine factors. An important challenge in translating these observations from preclinical studies into clinical treatment strategies relates to the fact that clinical studies are designed on top of established pharmacological therapy, whereas most experimental studies have tested novel interventions without concomitant drug regimens such as ACE inhibitors or beta-blockers. Therefore, animal studies may overestimate the effect of potential novel treatment strategies on LV remodelling and dysfunction, since established pharmacological therapies may act, in part, via identical or similar signalling pathways. Nevertheless, preclinical studies provide essential information for identifying potential novel targets, and their potential drawbacks, and are required for developing novel clinical treatment strategies to prevent or reverse LV remodelling and dysfunction.

Citations

62 citations in Web of Science®
72 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

47 downloads since deposited on 27 Mar 2009
13 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
DDC:610 Medicine & health
Language:English
Date:15 February 2009
Deposited On:27 Mar 2009 13:37
Last Modified:27 Nov 2013 21:34
Publisher:Oxford University Press
ISSN:0008-6363
Additional Information:This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Cardiovascular Research following peer review. The definitive publisher-authenticated version Cardiovasc Res. 2009 Feb 15;81(3):519-27 is available online at: http://cardiovascres.oxfordjournals.org/cgi/content/abstract/81/3/519
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:10.1093/cvr/cvn317
PubMed ID:19019834

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page